Advertisement PBR Staff Writer, Author at Pharmaceutical Business review - Page 1073 of 4440
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
 

All articles by  

RaQualia, CJ CheilJedang sign licensing deal

Under the contract, RaQualia has licensed the development, manufacturing and commercialization rights of 5-HT4 Partial Agonist (RQ-00000010) to CJ in India, Taiwan, Korea and South Asia. As per

FDA delays Pfizer Prevnar 13 approval

Prevnar 13 is indicated for active immunization for the prevention of pneumococcal disease in adult patients aged 50 and older. The FDA has extended the review period till

NAMN signs pact with DSV

NAMN is a provider of medical nutritional products like: dietary products, enteral clinical nutrition, disease specific nutrition for children, sick and elderly people. NAMN offers products under brands